NCT00470054View on ClinicalTrials.gov

Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

February 28, 2009

Study Completion Date

April 30, 2013

Conditions
Extensive Stage Small Cell Lung CancerLimited Stage Small Cell Lung CancerRecurrent Small Cell Lung Cancer
Interventions
DRUG

dasatinib

Given PO

Trial Locations (1)

60606

Cancer and Leukemia Group B, Chicago

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00470054 - Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter